You have recently set up a new disease service in your laboratory. What is the role of the UKGTN? Describe the process involved in submission & evaluation.

Slides:



Advertisements
Similar presentations
The European standards and guidelines for quality assurance Peter Williams President, ENQA.
Advertisements

A Health and Wellbeing Board for Leicestershire Cheryl Davenport Programme Director.
Project Appraisal Module 5 Session 6.
You have to provide a laboratory service for a Caucasian population of 3 million. How would you go about this? Describe your strategy for staff and equipment.
The Diagnostic Laboratory ……the ideal system……. Molecular Genetics Diagnostic Laboratory Exciting area of medical pathology Need to continually up-date.
The Gene Dossier a Potted History Fiona Stewart. The Start Was not very promising Quite a lot of hostility to the idea that anyone would consider telling.
Integrating the gender aspects in research and promoting the participation of women in Life Sciences, Genomics and Biotechnology for Health.
A friendly clinician has asked you to go about setting up a test for a genetic disorder previously characterised by a research laboratory. Discuss how.
SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.
Copyright © Healthcare Quality Quest, Proposed standards for a national clinical audit — How we got involved and what we have learned.
Informed Consent For Chemotherapy
NICE Guidance and Quality Standard on Patient Experience
Quality Data for a Healthy Nation by Mary H. Stanfill, RHIA, CCS, CCS-P.
Making difficult decisions - Obesity Treatment Eddie Coyle Jane Bray Sara Davies David Cline Jennifer Armstrong Heather Knox.
BACKGROUND AND AIM Website: Challenges in conducting a systematic review of the diagnostic accuracy of genetic tests: an example.
Development of internal control: methodology and responsibility
Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.
Commissioning products: What are they? How do they deliver better services for patients? Frances Flinter Chair, Medical Genetics CRG UKGTN Conference 22.
What is Risk Management? Whose responsibility is it in your institution? Mark Weatherley.
Global Poverty Action Fund Community Partnership Window Funding Seminar January 2014 Global Poverty Action Fund Community Partnership Window Funding Seminar.
CADTH Therapeutic Reviews
Integration, cooperation and partnerships
Purpose of the Standards
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
Equality Impact Assessment Training. History Stephen Lawrence case The Macpherson Report Police Force ‘institutionally racist’ - policies, procedures,
Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.
Jacquie Westwood UK Genetic Testing Network.  Approving UKGTN member labs who provide quality assured tests  Acknowledgment – UKGTN Laboratory Membership.
Internal Auditing and Outsourcing
Care Options for NHS Continuing Health Care (CHC) Wirral PCT Board – 12 February 2008 Tina Long - Director of Strategic Partnerships Sheila Hillhouse -
Steps towards measuring Equity in Testing Dr Mark Kroese UKGTN Public Health Advisor UK Genetic Testing Network Conference 22 nd November 2012.
Criteria and Standard.
Introduction to ISO New and modified requirements.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Organ donation Peter Bishop Clinical lead for organ donation.
Professional Certificate – Managing Public Accounts Committees Ian “Ren” Rennie.
Medical Audit.
1 Collaborative Provision and External Examining Nicola Clarke Centre for Academic Standards and Quality Enhancement (CASQE)
Guidelines for NHANES Research Proposal Submission by Natalie Dupree Margaret McDowell.
Developing a Referral Management Plan. Background Hospital referral rates in England have increased significantly over recent years, resulting in the.
Bowel Screening Project Overview Rhys Blake Head of Business and Service Development.
Introduction to Case Management. Why Case Management ?  The context of care is changing; we now have an ageing population and an increase in chronic.
Autistic Spectrum Disorder Strategic Action Plan 2008 – 2011: National Update David Poole ASD Regional Support Team Manager 6 th May 2010.
Piloting local partnership arrangements between Mental Health services and the Work Programme Sandra Harrild Newham IAPT Clinical Lead.
The ORPHANET Database: A Free Online Tool for Molecular Geneticists & Cytogeneticists Emma Gillaspy
Recommendation Methods Advisory Committee on Heritable Disorders and Genetic Diseases of Newborns and Children Ned Calonge, M.D., M.P.H.
Horizon Scanning: future skills and competences of the health workforce in Europe MATT EDWARDS and JOHN FELLOWS WP6, EU JA on Health Workforce Planning.
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
StagesOf Assessment Stages Of Assessment. The Stages of Assessment for the Single Assessment Process §Publishing information about services. §Completing.
Linking the learning to the National Standards for Safer Better Healthcare Joan Heffernan Inspector Manager Regulation – Healthcare Health Information.
NATIONAL INITIATIVES: BEST PRACTICE AND LESSONS LEARNED FROM SCOTTISH EXPERIENCE Alan MacDonald Vice Chairman Scottish Medicines Consortium Hard Choices.
Learning the lessons 2012 and 2014 procurements of audit services.
Partnership Health: Evaluation and possibilities for an adapted structure Agenda item 11 Madhavi Bajekal, ONS (UK) PH coordinator Directors of Social Statistics.
Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Quality Assurance. Define Quality (product & service) Exceeds the requirements of the customer. General excellence of standard or level. A product which.
The management of low-risk basal cell carcinomas in the community Implementing NICE guidance in general practice May 2010 NICE guidance on cancer services.
AssessPlanDo Review QuestionYesNo? Do I know what I want to evaluate and why? Consider drivers and audience Do I already know the answer to my evaluation.
Genetic testing and the United Kingdom Genetic Testing Network Professor Peter Farndon Chair UKGTN Presentation with images removed.
Quality Assurance for NHS Health Checks Sarah Stevens Public Health Registrar East of England QA Reference Centre.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
Healthcare Genetics in the NHS Landscape 1 st Gengage Network Conference June 2009 Dr Mike Winter Medical Director National Services Division.
TERMS OF REFERENCE - FINANCE COMMITTEE
CRUK working group MDT effectiveness proposal
Workforce Planning Framework
IS4550 Security Policies and Implementation
Dr Peter Groves MD FRCP Consultant Cardiologist
EUnetHTA Assembly May 2018.
Presentation transcript:

You have recently set up a new disease service in your laboratory. What is the role of the UKGTN? Describe the process involved in submission & evaluation of a gene dossier. Joan Forsyth 18/9/08

What is the UK Genetic Testing Network (UKGTN) Collaborative network of NHS labs that offer tests for human single gene germ disorders Aims to provide high quality and equitable laboratory services for patients and their families who require genetic advice, diagnosis and management. DoH supported establishment of UKGTN in UKGTN established the NHS directory of Molecular Genetic Testing –Allow equity in access to genetic testing across NHS –Funding responsibility of local specialist groups (purchasers of healthcare).

Core functions UKGTN Approval of labs for membership & audit of services provided –Dev simple methods/documentation to collect relevant lab data, produce annual reports Evaluation & recommendation of new genetic tests to be included/deleted from directory –constant review of gene dossiers Establish robust arrangements for the provision of molecular genetic services –Review of new developments & impact on NHS services, & identify commissioning mechanisms/procedures/policies Provide information on services of members Monitor, develop & manage UKGTN website & include a directory of test (levels of service) –ensuring fit for use by all relevant users & has appropriate links Evaluation of service development

How is the UKGTN organised? Network managed by UKTGN Steering Group –Members from a number of disciplines (clinical & molecular genetic, cytogenetics,DOH representatives, Genetic interest grps, NHS healthcare purchasers public health, Clinical Chemistry, Pathology, Biochemistry,Haematology, & reference labs) Subgroup of & accountable to National Genetics Commissioning Advisory Group (GenCAG)

UKGTN project team Pilot in labs submitted 85 GD, unexpected high number. To allow more time to consider applications a Project team introduced Includes project director, Lab coordinator, commissioning co- ordinator & 3 specialist advisors From working groups have supported the steering group, each with members from relevant professional & patient groups

Evaluation of new genetic tests UKGTN defines a genetic test as tests for single gene, germ line disorders where nucleic acid is the analyte Gene dossier (GD) process developed & a GD needs to be submitted for all tests the member wishes to offer to the network Standardised for the presentation of key information about the genetic test

ACCE model GD based on four components evaluated (ACCE model) & the Canadian experience of genetic test evaluation: Analytical validity Clinical validity Clinical utility Ethical, legal and social issues (ELSi) Genet Med Sep;7(7):

Analytical Validity Defines the ability of a test to accurately and reliably measure the genotype(s) of interest –Sensitivity – probability the test will be positive when the mutation is present –Specificity – probability the test will be negative when the mutation is not present Linked to quality assurance (QA) –Internal – reference standards, SNP checking, transfer checks –External – QA schemes, CPA registered laboratory

Clinical Validity Defines ability to detect/predict the presence or absence of the phenotype or clinical disease –Sensitivity – probability the test will be positive in an affected individual –Specificity – probability the test will be negative in an unaffected individual

Clinical Utility Defines the likelihood the test will lead to an improved outcome, & includes financial costs –Assessment or risk/benefits of genetic testing –Economic evaluation (business case)

ELSi Implications for relatives Insurance discrimination Stigmatisation based on genotype rather than phenotype

The criteria used by the Evaluation Panel Clinical details/prevalence of the condition Particular purpose of the test –diagnosis, treatment, prognosis and management, presymptomatic testing, risk assessment the complexity of the test Test criteria, clinical context in which test will be done- referrals from/population groups to be tested

The criteria used by the Evaluation Panel ACCE framework –the clinical sensitivity, specificity and predictive value of test –the utility of the test – how it adds to patient management and the availability of alternative diagnostic procedures –ethical, legal and social considerations Cost of the test

Process GD subgrp provides a summary back to steering group, which makes the final decision on dossier. Issues encountered with gene dossier applications include: –Use of published data rather than actual lab data in analytical evaluation –Lack of knowledge/technical limitations so only a proportion mutations identified by on test –Lack of analytical/validity data for significant no tests, because rare single gene disorder –Absence of controls in pilot studies/target pop poorly defined/estimates of disease prevalence of disease in target pop not provided –Financial data difficult to obtain –Limited discussion of Elsi issues List of approved tests placed before GenCAG for acceptance into directory & request made to healthcare purchasers to consider funding these tests

References How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network. European Journal of Human Genetics (2007) 15, 917–921.Mark Kroese, Ron L Zimmern, Peter Farndon, Fiona Stewart and Joanne Whittaker How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med Sep;7(7): Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J.